Back to search results

Colchicine for Calcium Pyrophosphate Deposition (CPPD) Disease

This study is looking into whether colchicine, a pill taken once daily, can help people with calcium pyrophosphate deposition (CPPD) disease. CPPD disease causes joint inflammation. Researchers want to see if colchicine can lower levels of a protein called interleukin 18 (IL-18) in your blood, which is a sign of inflammation. They also want to know if colchicine can reduce your joint pain. You might be able to join if you are 40 or older, have CPPD, and have experienced joint inflammation or pain in the last three months. The study will compare colchicine to a placebo (a pill with no medicine) to understand its effects. The current status of this study is unclear.

Study design
This study is comparing colchicine to a placebo in about 150 participants. It is an interventional study, meaning participants will receive a specific treatment.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Researchers will measure a specific protein in your blood at the beginning of the study and again at Week 24.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06855433

Colchicine to Reduce Your SympToms And Lower Levels of Inflammation, Zeroing in on Effective CPPD Disease Treatment

Recruiting
PHASE2Ages 40+InterventionalTreatment
Brigham and Women's Hospital
~150 participants
Updated 2026-07-09 on ClinicalTrials.gov
What's tested:Colchicine PillPlacebo

At a glance

Recruiting sites
5 of 5 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Interleukin 18 (IL-18)
Measured over Baseline and Week 24

Conditions

CPPD - Calcium Pyrophosphate Deposition Disease

Explore related trials

Calcium pyrophosphate deposition disease

Where it's being run

5 sites across 4 states
Massachusetts2
Alabama1
California1
Wisconsin1

Who to contact

Brenna Sharp de Flores, Senior Research Coordinator
[email protected]
617-732-6277
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Provide written informed consent
Fulfill ACR/EULAR 2023 CPPD classification criteria
Acute or chronic joint inflammation currently or in the past 3 months, not attributable to another condition (Joint Inflammation defined as: At least 1 joint this is swollen, red, or warm to the touch; with or without corresponding tenderness)
Pain visual analog scale (pain VAS) \>=30 at screening

Exclusion

Age \<40 years
Chronic diarrhea
Gout, rheumatoid arthritis, psoriatic arthritis, or cirrhosis
Ongoing use of colchicine and unwilling to undergo a 30-day wash-out period (note: patients using colchicine at screening can enroll if they agree to a 30-day wash-out before randomization)
Pregnant or breast-feeding
Use of methotrexate, hydroxychloroquine, tocilizumab or canakinumab in the past 4 weeks
Use of anakinra, oral glucocorticoid, or intra-articular steroid in the past 1 week
Ongoing use of strong CYP3A4 inhibitors per FDA package insert for colchicine
Ongoing use of P-glycoprotein inhibitors per FDA package insert for colchicine
Known allergy to colchicine
Planned joint surgery in the next 6 months
CPPD clinical presentation isolated to Crowned Dens Syndrome with no additional peripheral joint involvement
Screening labs with any of the following:
Patient is considered by investigator to be an unsuitable candidate for the study for any reason

What this trial measures

  • Interleukin 18 (IL-18)Baseline and Week 24

    Serum IL-18